Johnson & Johnson's (NYSE:JNJ) recently reported earnings and the massive health-care conglomerate posted another strong performance. Revenue grew 3% and earnings popped 8%, beating analysts' expectations. But is there trouble lurking beneath the rosy headlines?
The pharma segment, possibly the industry's strongest, posted its sixth quarter of double-digit growth out of the past seven. Those 11% gains help offset weakness in the consumer segment, which declined 1%, and a slightly disappointing showing of 2% growth from medical devices.
In this episode of Market Check-Up, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass break down J&J's quarter, giving highlights and lowlights of each division's performance. This includes the launch of Michael's newest favorite medical device, the Thermacool Smarttouch Catheter, as well as the company's asset sales. Watch and find out how investors should react to this news and what Johnson & Johnson needs to do to keep up the positive earnings surprises.
Who doesn't love a great dividend stock like Johnson & Johnson?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.